Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,290 shares of the biopharmaceutical company’s stock after selling 89 shares during the quarter. Regeneron Pharmaceuticals accounts for about 1.7% of Washington Trust Advisors Inc.’s investment portfolio, making the stock its 17th largest holding. Washington Trust Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $20,864,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. One Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 2.5% during the fourth quarter. One Capital Management LLC now owns 12,486 shares of the biopharmaceutical company’s stock worth $8,894,000 after purchasing an additional 310 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $65,180,000. Cullen Frost Bankers Inc. lifted its stake in Regeneron Pharmaceuticals by 1,244.8% in the fourth quarter. Cullen Frost Bankers Inc. now owns 6,307 shares of the biopharmaceutical company’s stock valued at $4,493,000 after buying an additional 5,838 shares during the last quarter. Arizona State Retirement System lifted its stake in Regeneron Pharmaceuticals by 0.6% in the fourth quarter. Arizona State Retirement System now owns 31,224 shares of the biopharmaceutical company’s stock valued at $22,242,000 after buying an additional 185 shares during the last quarter. Finally, Aigen Investment Management LP lifted its stake in Regeneron Pharmaceuticals by 780.6% in the fourth quarter. Aigen Investment Management LP now owns 6,367 shares of the biopharmaceutical company’s stock valued at $4,535,000 after buying an additional 5,644 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $687.15 on Thursday. The company has a market capitalization of $75.12 billion, a PE ratio of 17.95, a P/E/G ratio of 2.34 and a beta of 0.08. The company has a 50 day simple moving average of $696.58 and a two-hundred day simple moving average of $857.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $11.86 EPS. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Bernstein Bank cut their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.